Sandbox Reserved 963: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 1: Line 1:
{{Sandbox_ESBS}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->
{{Sandbox_ESBS}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->
==Structure of anti-amyloid-beta Fab WO2 (Form A, P212121)==
==Structure of anti-amyloid-beta Fab W-02 (Form A, P212121)==
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
'''Alzheimer's disease (AD)''', is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's is difficulty remembering recently learned information. As the patient with Alzheimer’s disease ages, many symptoms can appear: speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation.
'''Alzheimer's disease (AD)''', is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's disease is the difficulty in remembering recently learned information. As the patient with Alzheimer’s disease ages, symptoms such as speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation, can appear.


Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist. The benefit from their use is small. No medication has been clearly shown to delay or halt the progression of the disease.
Acetylcholinesterase inhibitors such as [http://en.wikipedia.org/wiki/Rivastigmine rivastigmine], [http://en.wikipedia.org/wiki/Tacrine tacrine], [http://en.wikipedia.org/wiki/Donepezil donepezil] and [http://en.wikipedia.org/wiki/Galantamine galantamine] or, [http://en.wikipedia.org/wiki/Memantine memantine], which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.  


Acetylcholinesterase inhibitors such as [rivastigmine], tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.  
However, many groups of researchers are seeking a solution to this problem and most of them are currently focused on the activity of a small peptide called [http://en.wikipedia.org/wiki/Amyloid_beta Amyloid ß (Aß)].


However, many groups of researchers are seeking a solution to this problem and most of them are currently focused on the activity of a small peptide called Amyloid ß.
The known cause of this disease is depicted as the presence of the amyloid plaques found in the brains of Alzheimer patients, which are composed of Aß.
 
These are peptides  of 36–43 amino acids, obtained via proteolysis of [http://en.wikipedia.org/wiki/Amyloid_precursor_protein Amyloid Precursor Protein (APP)].
The known cause of this disease is depicted as the presence of the amyloid plaques found in the brains of Alzheimer patients, which are composed of Amyloid ß (Aß).
An immunologic approach to the disease is made. Researchers have developped a monoclonal antibody, W-02 which can bind specifically to the Aß’s epitope, thus leading the complex to be phagocyted.
These are peptides  of 36–43 amino acids, obtained via proteolysis of Amyloid Precursor Protein (APP).
An immunologic approach to the disease is made. Researchers have developped a monoclonal antibody which can bind specifically to the Aß’s epitope.
Alzheimer's disease (AD), is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's is difficulty remembering recently learned information. As the patient with Alzheimer’s disease ages, many symptoms can appear: speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation.
 
Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist. The benefit from their use is small. No medication has been clearly shown to delay or halt the progression of the disease.
 
Acetylcholinesterase inhibitors such as [http://en.wikipedia.org/wiki/Rivastigmine], tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.
 
However, many groups of researchers are seeking a solution to this problem and most of them are currently focused on the activity of a small peptide called Amyloid ß.
 
The known cause of this disease is depicted as the presence of the amyloid plaques found in the brains of Alzheimer patients, which are composed of Amyloid ß (Aß).
These are peptides  of 36–43 amino acids, obtained via proteolysis of Amyloid Precursor Protein (APP).
An immunologic approach to the disease is made. Researchers have developped a monoclonal antibody which can bind specifically to the Aß’s epitope.


== Biological Function ==
== Biological Function ==
Retrieved from "https://proteopedia.org/Sandbox_Reserved_963"